赞比亚HIV-HBV合并感染者接受ART后乙肝功能性治愈率高
在赞比亚284名启动含替诺福韦ART的HIV-HBV合并感染成人中,中位基线CD4+计数为202 cells/mm3,41.6%为HBeAg阳性;治疗2年内29人(10.2%)实现HBV功能性治愈。多因素分析显示基线CD4<350 cells/mm3、女性及较低基线HBV DNA与功能性治愈几率增加相关。
要点
- HIV-HBV合并感染者接受含替诺福韦ART后2年内HBV功能性治愈率可达10.2%。
- 基线CD4<350 cells/mm3、女性、较低HBV DNA与功能性治愈几率增加相关。
- ART期间的免疫恢复可能驱动比HBV单感染治疗更高的功能性治愈率。
核心结论
- HIV-HBV合并感染者接受含替诺福韦ART后,HBV功能性治愈率较高,免疫恢复可能是驱动因素。
研究设计与样本
- 研究纳入赞比亚284名启动含替诺福韦ART的HIV-HBV合并感染成人,中位基线CD4+计数为202 cells/mm3,41.6%为HBeAg阳性。
主要发现
- 治疗2年内,29名(10.2%)参与者实现HBV功能性治愈(确认HBsAg丢失)。
- 多因素分析中,基线CD4<350 cells/mm3、女性、较低基线HBV DNA与功能性治愈几率增加相关。
临床怎么用
- 对于HIV-HBV合并感染者,启动含替诺福韦ART后应关注HBV功能性治愈可能,尤其CD4<350 cells/mm3、女性及低HBV DNA者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.
引用
- Chihota BV, Wandeler G, Chilengi R, et al. High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. J Infect Dis. 2020. PMID: 31613956. doi:10.1093/infdis/jiz450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。